Skip to main content

Nine-month interim report (Q3) 2020

Written by Customer Service on . Posted in Public Companies.

Bemærk venligst, at rapporten udelukkende findes på engelsk.ALK reports 52% tablet growth and 61% earnings growth in Q3 (unaudited)ALK’s revenue returned to growth in Q3 with 7% revenue growth as sales across the tablet portfolio grew 52%, led by Europe and International markets which were resilient to pandemic-related market constraints. This result is achieved despite the continuing negative impact of COVID-19 on its legacy business, predominantly in the USA. ALK’s full-year financial outlook has been updated.Q3 2020 highlightsTotal revenue was up 7% organically in local currencies at DKK 772 million (739). Planned product discontinuations reduced growth by approximately 4 p.p. Currencies reduced reported growth by 2 p.p.Tablet sales grew by 52% to DKK 281 million (185), while combined SCIT and SLIT-drops sales were down 11% on the effects of COVID-19 and planned portfolio rationalisation.Operating profit (EBITDA) exceeded expectations and grew 61% to DKK 58 million (36), principally on delayed R&D expenditure and other savings on planned activities due to the impact of COVID-19.Free cash flow, at DKK minus 88 million (minus 35) was ahead of plan, driven by higher earnings, and the re-phasing of investments and tax payments.Revenue for the first nine months was up 6%, EBITDA was up 72% at DKK 331 million (193) and free cash flow was DKK minus 67 million (minus 184).Update on the effects of COVID-19Many markets still have COVID-19 countermeasures in place. Although patients are beginning to return to allergy clinics for treatment, access to clinics in some markets remains constrained to varying degrees.Sales of legacy products remain under pressure, largely due to the constraints the pandemic has placed on the willingness and ability of patients to visit clinics. Sales in the USA are particularly impacted, and ALK estimates that the 2020 full-year total value of missed US sales will be more than DKK 100 million.Sales of tablets, which can be self-administered at home, remains resilient and were actually boosted in some markets leading to continued market share gains and further consolidation of ALK’s leadership.Product supply remain highly resilient and ALK is maintaining robust inventories of its products and supplies.ALK is now seeing a tangible impact from COVID-19 on clinical development activities due to challenges in recruiting clinical trial participants, which affects the ability to conduct trials as planned.Updated 2020 financial outlookIn light of the results for the first nine months and the ongoing effects of COVID-19, ALK is upgrading its EBITDA and cash flow outlook while narrowing its revenue growth outlook. ALK now expects:Organic revenue growth is expected at around 8% equating to approximately DKK 3.5 billion (previously towards the lower end of 8-12%).Operating profit (EBITDA) is now expected to be DKK 350-400 million (previously 300-350).Free cash flow is now expected at approximately DKK 0 million (previously negative ~200), reflecting the higher earnings and a positive change to working capital.Hørsholm, 11 November 2020ALK-Abelló A/SComparative figures for 2019 are shown in brackets. Revenue growth rates are organic and are stated in local currencies, unless otherwise indicatedFor further information, contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Jeppe Ilkjær, mobile +45 3050 2014Today, ALK is hosting a conference call for analysts and investors at 1.30 p.m. (CET) at which Management will review the financial results and the outlook. The conference call will be audio cast on https://ir.alk.net. Participants for the audio cast are kindly requested to call in before 1.25 p.m. (CET). Danish participants should call in on tel. +45 3544 5577 and international participants should call in on tel. +44 333 300 0804 or +1 631 913 1422. Please use the Participant Pin Code: 40890398#. The conference call will also be webcast live on our website, where the related presentation will be made available shortly before the call begins.
Vedhæftet filFM_12_20UK_11112020

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.